Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Gains from Investment Securities (2020 - 2025)

Historic Gains from Investment Securities for Oncology Institute (TOI) over the last 6 years, with Q3 2025 value amounting to $150000.0.

  • Oncology Institute's Gains from Investment Securities rose 85000.0% to $150000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $199000.0, marking a year-over-year increase of 13344.54%. This contributed to the annual value of -$619000.0 for FY2024, which is 2291.41% up from last year.
  • Per Oncology Institute's latest filing, its Gains from Investment Securities stood at $150000.0 for Q3 2025, which was up 85000.0% from $53000.0 recorded in Q2 2025.
  • In the past 5 years, Oncology Institute's Gains from Investment Securities ranged from a high of $203000.0 in Q3 2023 and a low of -$39.4 million during Q1 2022
  • Its 5-year average for Gains from Investment Securities is -$5.0 million, with a median of -$47000.0 in 2024.
  • Per our database at Business Quant, Oncology Institute's Gains from Investment Securities plummeted by 10669459.46% in 2022 and then soared by 85000.0% in 2025.
  • Quarter analysis of 5 years shows Oncology Institute's Gains from Investment Securities stood at -$25.3 million in 2021, then surged by 78.7% to -$5.4 million in 2022, then surged by 99.8% to -$11000.0 in 2023, then crashed by 327.27% to -$47000.0 in 2024, then surged by 419.15% to $150000.0 in 2025.
  • Its Gains from Investment Securities stands at $150000.0 for Q3 2025, versus $53000.0 for Q2 2025 and $43000.0 for Q1 2025.